COSMETIC COMPOSITION FOR ORAL ADMINISTRATION FOR REINFORCING THE SKIN BARRIER

Abstract

This invention relates to the cosmetic use by oral route of a combination of lycopene and manganese to prevent a decrease of and/or reinforce the barrier function of the skin.

Claims

1. A cosmetic method to prevent a decrease of and/or to reinforce the barrier function of the skin comprising at least one step of administering, simultaneous, separate or sequential, to an individual by oral route a combination of lycopene and manganese as an agent to prevent the decrease of and/or to reinforce the barrier function of the skin.

2. A cosmetic method to reinforce the protection of the skin with regards to external aggressions comprising at least one step of administering, simultaneous, separate or sequential, to an individual by oral route of a combination of lycopene and manganese as an agent to reinforce the protection of the skin with regards to external aggressions.

3. The cosmetic method according to claim 1, to prevent and/or to reduce a cutaneous discomfort of a skin.

4. The cosmetic method according to claim 3, wherein the cutaneous discomfort is characterized by tautness, tingling, heating and/or itching.

5. The cosmetic method according to claim 1, to improve the state of hydration of the skin.

6. The cosmetic method according to claim 1, wherein the combination of lycopene and of manganese is in the form of a cosmetic composition.

7. The cosmetic method according to claim 6, wherein the molar ratio of lycopene over manganese in the composition is between 1/10 and 10/1.

8. The cosmetic method according to claim 1, wherein the lycopene used comes from a lycopene-rich tomato extract.

9. The cosmetic method according to claim 1, wherein the manganese is in the form of an inorganic manganese salt.

10. The cosmetic method according to claim 1 to prevent a decrease and/or reinforce the barrier function of the skin, wherein the administering of the combination of lycopene and of manganese is simultaneous.

11. The cosmetic method according to claim 1, wherein said administration is daily for a period of 1 to 16 weeks.

12. A combination of lycopene and manganese for its simultaneous, sequential or separate use, by oral route, for the prevention of a decrease of and/or for the reinforcing of the barrier function of damaged skin.

13. A composition comprising a combination of lycopene and manganese for its use by oral route, for the prevention of a decrease and/or for the reinforcing of the barrier function of damaged skin.

14. The cosmetic method according to claim 2, to prevent and/or to reduce a cutaneous discomfort of a skin.

15. The cosmetic method according to claim 2, to improve the state of hydration of the skin.

16. The cosmetic method according to claim 2, wherein the combination of lycopene and of manganese is in the form of a cosmetic composition.

17. The cosmetic method according to claim 3, wherein the combination of lycopene and of manganese is in the form of a cosmetic composition.

18. The cosmetic method according to claim 4, wherein the combination of lycopene and of manganese is in the form of a cosmetic composition.

19. The cosmetic method according to claim 5, wherein the combination of lycopene and of manganese is in the form of a cosmetic composition.

20. The cosmetic method according to claim 16, wherein the molar ratio of lycopene over manganese in the composition is between 1/10 and 10/1.

Description

EXAMPLES

Example 1: Analysis of the Synergic Effect of the Lycopene and Manganese Combination on the Expression of SPRR2D

[0065] This example shows that the combination of lycopene and manganese makes it possible to increase in a synergic manner the gene expression of SPRR2D in human keratinocytes.

[0066] The effect of the lycopene and manganese was studied separately then in combination on the gene expression profile (RNAm) of human keratinocytes NHEK (normal human epidermal keratinocytes) per RT-qPCR. The results are presented in table 1.

[0067] A 24-well plate was seeded with keratinocytes then placed into culture for 24 hours. The culture medium was then replaced with the test medium comprising according to the cases 0 (negative control), one or two tested compounds. The cells were incubated in this test medium for 18 hours then washed and frozen at −80° C. Each condition was carried out in triplicate. Two samples of each triplicate were grouped together, then the RNAm was extracted therefrom using TriPure Isolation Reagent® according to the supplier's recommendations. The ADNc was synthesized via reverse transcription of total RNA by “Transcriptor Reverse Transcriptase” from Roche. Then a quantitative PCR was performed in the presence of a fluorophore. The incorporation of flurophore in the amplified DNA was measured during the PCR cycles. Two genes were used as a reference (RPS28 ad GADPH), in order to standardize the results. As such the level of expression of the studied genes was compared to the average level of expression of these two reference genes for all of the conditions tested.

[0068] For this test, the source of lycopene is Lyc-o-Mato marketed by Lycored and the source manganese is manganese sulfate.

TABLE-US-00001 TABLE 1 Expression expressed as a percentage in relation to the conditions without added compound Lyc-o-Mato 10 μg/ml + Lyc-o- Manganese Manganese Mato Sulfate Sulfate 10 μg/ml 10 μg/ml 10 μg/ml Control (GAPDH) 98 96 100 Control (RPS28) 108 117 99 SPRR2D 511 106 1718

[0069] These results therefore show a synergic effect between the lycopene and the manganese on the expression of SPRR2D in vitro.

Example 2

[0070] Solar Formula for Administration by Oral Administration (Tablets):

TABLE-US-00002 Daily dose Trade name (mg/day) Ingredients: Lycopene Lactolycopene 2% 4 Manganese Manganese Sulfate 2.3 Monohydrate, USP/EP, Low HM powder Vitamin C Ascorbic Acid 90% 40 Granulation Lutein FloraGlo Lutein 2 10% CW/S-TG Excipients: Dicalcium Emcompress 250 phosphate dihydrate Microcrystalline Prosolv 160 cellulose Croscarmellose Vivasol GFLM 20 sodium Silicon dioxide ProSolv HD90 10 Coloring agent Opadry white 40

Example 3

[0071] Formula for Reinforcing the Barrier Function of the Skin, for Oral Administration (Capsules) Comprising Probiotic ST11

TABLE-US-00003 Daily dose Trade name (mg/day) Ingredients: Lycopene Lactolycopene 2% 4 Manganese Manganese Sulfate 2.3 Monohydrate, USP/EP, Low HM powder Culture in ST11 50 powder of (contribution Lactobacillus in ST11: min. paracasei ST11 1E+09 cfu/d) Excipients: Colloidal silicon Aerosil 200 5 dioxide Pharma Corn flour C*Gel LM 03411 200 Magnesium Ligamed MF-2-V 3 stearate

Example 4

[0072] Oral formula for reinforcing the protection of atopic skins between the phase of pharmacologic treatment and as such prolong the remission phases between atopic eruptions. The dosage is one tablet per day for 3 months.

TABLE-US-00004 Daily Trade dose name (mg/day) Ingredients: Lycopene Lactolycopene 4 2% Manganese Manganese 2.3 Sulfate Monohydrate, USP/EP, Low HM powder Excipients: Dicalcium Emcompress 250 phosphate dihydrate Microcrystalline Prosolv 250 cellulose Croscarmellose Vivasol 60 sodium GFLM Silicon dioxide ProSolv HD90 17 Colorants Opadry white 30